← Krystal Biotech, Inc. (KRYS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Krystal Biotech, Inc. (KRYS)
Biological Products, (No Diagnostic Substances) · market cap $10.2B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
7
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
Krystal Biotech (KRYS) is a ~$10.9B market-cap commercial-stage rare disease biotech with 275 employees. Its lead asset, topical beremagene geperpavec (B-VEC), is already generating substantial revenue in Dystrophic Epidermolysis Bullosa (DEB), with 2025 revenues of $389M and net income of $205M. The company has a pipeline extending into neurotrophic keratitis (KB801), non-small cell lung cancer (KB707), and a next-generation DEB asset (KB803), with key data readouts expected in late 2026 and early 2027.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · KB803imp 9/10
- 2026-12-15 (est.)Phase 2 · KB801imp 7/10
- 2027-02-15 (est.)Phase 2 · KB707imp 7/10
- 2027-07-15 (est.)Phase 2 · KB707imp 7/10
- 2027-07-15 (est.)Phase 2 · Opdualagimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KB801 | Phase 2 | Neurotrophic Keratitis |
| KB707 | Phase 2 | Lung Cancer, Non-small Cell |
| Topical beremagene geperpavec | Phase 3 | Dystrophic Epidermolysis Bullosa |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Phase 3 | Dystrophic Epidermolysis Bullosa |
| Opdualag | Phase 2 | Cancer |
| KB803 | Phase 3 | Dystrophic Epidermolysis Bullosa |
| KB304 | Phase 2 | Wrinkles in Decolletage |
Price & technical context
3-month
-12.5%
6-month
+25.7%
12-month
+82.6%
52-wk range
$180.57–$378.15
vs 50-day MA
-4.3%
vs 200-day MA
+8.8%
Realized vol
37.7%
Max drawdown
-38.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KRYS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.